Depresja a reumatoidalne zapalenie stawów Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2020
Słowa kluczowe:
tocilizumab, reumatoidalne zapalenie stawów, depresja, interleukina 6
##plugins.themes.bootstrap3.article.main##
Abstrakt
Uporczywy ból, zmęczenie oraz postępujące ograniczenie zdolności do samodzielnej egzystencji często powodują u pacjentów z reumatoidalnym zapaleniem stawów dramatyczne pogorszenie jakości życia. Wyraźnie częstsze występowanie zaburzeń psychosomatycznych u tych chorych mogło się wydawać prostą konsekwencją powyższych aspektów tego schorzenia. Odkrycie roli, jaką w rozwoju depresji odgrywają cytokiny prozapalne, takie jak: interleukina 6, interleukina 1, TNF-α czy interleukina 17, stworzyło przestrzeń do poszukiwania zależności między zaburzeniami nastroju a reumatoidalnym zapaleniem stawów. Podobieństwo profilu cytokin w odniesieniu zarówno do zaburzeń depresyjnych, jak i reumatoidalnego zapalenia stawów dawało także nadzieję na złagodzenie objawów psychosomatycznych dzięki zastosowaniu leków antycytokinowych. Antagoniści receptora IL-6, cytokiny kluczowej dla rozwoju zaburzeń depresyjnych, są szczególnie skuteczni w tym zakresie, nie tylko wpływając na istotne zmniejszenie aktywności stanu zapalnego, ale także łagodząc objawy depresji, często stwierdzane wśród chorych na reumatoidalne zapalenie stawów.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Guzera , Z., & Święcicki, Łukasz. (2020). Depresja a reumatoidalne zapalenie stawów . Medycyna Faktów , 13(1(46), 74-80. https://doi.org/10.24292/01.MF.0120.8
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. van Hoogmoed D., Fransen J., Bleijenberg G., van Riel P.: Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology 2010; 49: 1294-1302.
2. Atal S.A., Ceceli E., Okumu M. et al.: The evaluation of pain in patients with rheumatoid arthritis. Pain Pract. 2009; 9: 31.
3. Jacobi C.E., Mol G.D., Boshuizen H.C. et al.: Impact of socioeconomic status on the course of rheumatoid arthritis and on related use of health care services. Arth. Care Res. 2003; 49: 567-573.
4. Vallerand I.A., Patten S.B., Barnabe Ch.: Depression and the risk of rheumatoid arthritis. Curr. Opin. Rheumatol. 2019; 31(3): 279-284.
5. Gallagher P., Reid K.S., Ferrier I.N.: Neuropsychological functioning in health and mood disorder: modulation by glucocorticoids and their receptors. Psychoneuroendocrinology 2009; 34(supl. 1): S196-207.
6. Dougados M., Soubrier M., Antunez A., Hotopf M.: Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 2014; 73(1): 62-68. DOI: 10.1136/annrheumdis-2013-204223.
7. Matcham F., Rayner L., Steer S.,Hotopf M.: The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52: 2136-2148.
8. Covic T., Pallant J.F., Tennant A. et al.: Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales. BMC Musculoskelet. Disord. 2009; 10: 18.
9. Kwiatkowska B., Kłak A., Raciborski F., Maślińska M.: The prevalence of depression and insomnia symptoms among patients with rheumatoid arthritis and osteoarthritis in Poland: a case control study. Psychol. Health Med. 2019; 24(3): 333-343. DOI: 10.1080/13548506.2018.1529325.
10. Matcham F., Norton S., Steer S., Hotopf M.: Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis. BMC Musculoskelet. Disord. 2016; 17: 224. DOI: 10.1186/s12891-016-1083-y.
11. Hepgul N., Mondelli V., Pariante C.M.: Psychological and biological mechanisms of cytokine induced depression. Epidemiol. Psichiatr. Soc. 2010; 19: 98-102.
12. Maes M., Anderson G., Kubera M., Berk M.: Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin. Ther. Targets 2014; 18(5): 495-512.
13. Kwiatkowska B., Kłak A., Maślińska M. et al.: Factors of depression among patients with rheumatoid arthritis. Reumatologia 2018; 56(4): 219-227. DOI: 10.5114/reum.2018.77973.
14. Hurst N.P., Kind P., Ruta D.: Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br. J. Rheumatol. 1997; 36: 551-559.
15. Farheen K., Agarwal S.K.: Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J. Manag. Care Pharm. 2011; 17(9 suppl. B): S09-13.
16. DiMatteo M., Lepper H.S., Croghan T.W.: Depression is a risk factor for noncompliance with medical treatment:meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 2000; 160: 2101-2107.
17. Matcham F., Davies R., Hotopf M. et al.: The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology biologics register. Rheumatology 2018; 57(5): 835-843.
18. Marrie R.A., Hitchon C.A., Walld R. et al.: Increased burden of psychiatric disorders in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2018; 70: 970-978.
19. Deb A., Dwibedi N., LeMasters T. et al.: Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis. Am. Health Drug Benefits 2019; 12(1): 30-38.
20. Li P., Zheng Y., Chen X.: Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front. Pharmacol. 2017; 8: 460.
21. Figueiredo-Braga M., Cornaby C., Cortez A. et al.: Influence of biological therapeutics, cytokines, and disease activity on depression in rheumatoid arthritis. J. Immunol. Res. 2018: 5954897.
22. Maes M., Scharpe S., Meltzer H.Y. et al.: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic- pituitary-adrenal axis in severe depression. Psychiatry Res. 1993; 49: 11-27.
23. Choy E.H.S., Calabrese L.H.: Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford) 2018; 57: 1885-1895.
24. Navarro G., Taroumian S., Barroso N. et al.: Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin. Arthritis Rheum. 2014; 43: 458-469.
2. Atal S.A., Ceceli E., Okumu M. et al.: The evaluation of pain in patients with rheumatoid arthritis. Pain Pract. 2009; 9: 31.
3. Jacobi C.E., Mol G.D., Boshuizen H.C. et al.: Impact of socioeconomic status on the course of rheumatoid arthritis and on related use of health care services. Arth. Care Res. 2003; 49: 567-573.
4. Vallerand I.A., Patten S.B., Barnabe Ch.: Depression and the risk of rheumatoid arthritis. Curr. Opin. Rheumatol. 2019; 31(3): 279-284.
5. Gallagher P., Reid K.S., Ferrier I.N.: Neuropsychological functioning in health and mood disorder: modulation by glucocorticoids and their receptors. Psychoneuroendocrinology 2009; 34(supl. 1): S196-207.
6. Dougados M., Soubrier M., Antunez A., Hotopf M.: Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 2014; 73(1): 62-68. DOI: 10.1136/annrheumdis-2013-204223.
7. Matcham F., Rayner L., Steer S.,Hotopf M.: The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52: 2136-2148.
8. Covic T., Pallant J.F., Tennant A. et al.: Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales. BMC Musculoskelet. Disord. 2009; 10: 18.
9. Kwiatkowska B., Kłak A., Raciborski F., Maślińska M.: The prevalence of depression and insomnia symptoms among patients with rheumatoid arthritis and osteoarthritis in Poland: a case control study. Psychol. Health Med. 2019; 24(3): 333-343. DOI: 10.1080/13548506.2018.1529325.
10. Matcham F., Norton S., Steer S., Hotopf M.: Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis. BMC Musculoskelet. Disord. 2016; 17: 224. DOI: 10.1186/s12891-016-1083-y.
11. Hepgul N., Mondelli V., Pariante C.M.: Psychological and biological mechanisms of cytokine induced depression. Epidemiol. Psichiatr. Soc. 2010; 19: 98-102.
12. Maes M., Anderson G., Kubera M., Berk M.: Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin. Ther. Targets 2014; 18(5): 495-512.
13. Kwiatkowska B., Kłak A., Maślińska M. et al.: Factors of depression among patients with rheumatoid arthritis. Reumatologia 2018; 56(4): 219-227. DOI: 10.5114/reum.2018.77973.
14. Hurst N.P., Kind P., Ruta D.: Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br. J. Rheumatol. 1997; 36: 551-559.
15. Farheen K., Agarwal S.K.: Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J. Manag. Care Pharm. 2011; 17(9 suppl. B): S09-13.
16. DiMatteo M., Lepper H.S., Croghan T.W.: Depression is a risk factor for noncompliance with medical treatment:meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 2000; 160: 2101-2107.
17. Matcham F., Davies R., Hotopf M. et al.: The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology biologics register. Rheumatology 2018; 57(5): 835-843.
18. Marrie R.A., Hitchon C.A., Walld R. et al.: Increased burden of psychiatric disorders in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2018; 70: 970-978.
19. Deb A., Dwibedi N., LeMasters T. et al.: Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis. Am. Health Drug Benefits 2019; 12(1): 30-38.
20. Li P., Zheng Y., Chen X.: Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front. Pharmacol. 2017; 8: 460.
21. Figueiredo-Braga M., Cornaby C., Cortez A. et al.: Influence of biological therapeutics, cytokines, and disease activity on depression in rheumatoid arthritis. J. Immunol. Res. 2018: 5954897.
22. Maes M., Scharpe S., Meltzer H.Y. et al.: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic- pituitary-adrenal axis in severe depression. Psychiatry Res. 1993; 49: 11-27.
23. Choy E.H.S., Calabrese L.H.: Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford) 2018; 57: 1885-1895.
24. Navarro G., Taroumian S., Barroso N. et al.: Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin. Arthritis Rheum. 2014; 43: 458-469.